Something unusual happened in October: the parts of the market farthest from AI surged while megacap tech stalled, and now a record-breaking gap is sitting right in the path of the biggest…
Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.89 during the trading…
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported…
UnitedHealth Group (NYSE:UNH | UNH Price Prediction) shares are up 4% to $395.19 after the health insurer topped Q3 2026 profit estimates and raised its full-year outlook. The beat came on the…
Better Medicare quality scores are reordering the managed care rankings, and shares of Humana (NYSE:HUM | HUM Price Prediction) are setting the pace. Humana stock is at $447, up 15% early in…
A fresh analyst upgrade is sending Humana (NYSE:HUM | HUM Price Prediction) shares sharply higher, and the rally stands apart from a quiet managed care group. Humana stock is up 7% to…
Novo Nordisk (NYSE:NVO | NVO Price Prediction) laid out its long-term growth strategy at a capital markets day in London Monday morning, and the plan didn’t calm investor worries about the company’s…
Energy is the year’s best-performing sector, and on Wednesday the options market bet heavily that it is about to break. Volume in Energy Select Sector SPDR (NYSEARCA:XLE) options ran roughly 70% above…
Gas prices just posted their biggest monthly jump in years, and a Wall Street economist has put a precise dollar figure on the oil price that tips the American consumer into recession…
TPG just bought into the exact Optum clinics that derailed UnitedHealth's profits, and management is hours away from reaffirming guidance that could either validate the deal or reopen a wound investors hoped…
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same…
Jim Cramer called the JNJ dip a buying opportunity live on air, but the data behind his reasoning had already been published hours earlier, and the stock's recent performance tells a very…
XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a…
A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have…
The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker:…
